Craft
  • Home
  •  / Passage Bio
Passage Bio

Passage Bio

Market Capitalization

$75.1 M

2022-09-21

Passage Bio Summary

Company summary

Overview
Passage Bio is a genetic medicines company developing therapies for the treatment of rare monogenic central nervous system diseases. Passage Bio develops a portfolio of 5 rare disease indications in the neuro/CNS genetic space through IND-enabling studies using AAV technology and know-how.
Type
Public
Founded
2018
HQ
Philadelphia, PA, US | view all locations
Website
https://www.passagebio.com/home/default.aspx
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Andrea Campanile, Vice President Clinical Operations

  • Alex Fotopoulos

    Alex Fotopoulos, Chief Technical Officer

  • James M. Wilson

    James M. Wilson, Chief Scientific Advisor

    • Edgar B. Cale

      Edgar B. Cale, Interim Chief Executive Officer, General Counsel and Corporate Secretary

    LocationsView all

    1 location detected

    • Philadelphia, PA HQ

      United States

      2001 Market St

    Passage Bio Financials

    Summary financials

    Net income (Q2, 2022)
    (₩39.5M)
    Cash (Q2, 2022)
    ₩91.1M
    EBIT (Q2, 2022)
    (₩39.8M)
    Enterprise value
    $11.4M

    Footer menu